Table 2.

Alternative TKIs investigated in patients with advanced imatinib refractory GIST

Drug	N	Number of prior therapies (median)	Phase	Randomized	Other arm	RR	CBR	PFS (median)	OS (median)	Year	References
Pazopaniba	25	2 (at least)	II	No	–	SD-48%	NPR-17%	1.9 mo	10.7 mo	2014	[54]
Pazopaniba	81	2	II	Yes	BSC	SD Pazopanib-84%	84%	3.4 versus 2.3 (p = 0.03)	17.8 versus 12.9 mo	2016	[55]
						BSC-71%
Cabozantiniba	50	2	II	No	–	PR-14%	80%	6.0 mo	14.4 mo	2019	[56]
						SD-66%
Sorafeniba	31	2	II	No	–	PR-13%	36% at 24 wks	4.9 mo	9.7 mo	2012	[57]
						SD-52%
Sorafeniba	38	2	II	No	–	PR-13%	68%	5.2 mo	11.6 mo	2011	[58]
						SD-55%
Nilotiniba	35	2	II	No	–	PR-3%	29% at 24 wks	3.7 mo	10 mo	2011	[59]
						SD-26%
Dasatiniba	47	2	II	No	–	PR-32%	56%	1.8 mo	19 mo	2011	[41]
						SD-24%
Ponatinib	45	3	II	No	–	PR-7%	37%	2.0 mo	13.5 mo	2014	[60]
Masitinib	44	1	II	Yes	Sunitinib	–	–	3.7 versus 1.9 mo	29.8 versus 17.4 mo	2014	[61]
Vatalanib	45	1	II	No	–	PR-4.4%	40%	4.5 mo (mTTP)	–	2011	[62]
						SD-35.6%
Dovitinib	30	2	II	No	–	PR-3%	13%	3.6 mo	9.7 mo	2014	[63]
						SD 10%
Avapritiniba	476	2 or 3	III	Yes	Regorafenib	PR—17.1%(avapritinib) versus 7.2% (regorafenib)		4.2 mo (A) versus 5.6 mo (R)	–	2020	[34]

wt, wild type; N, number of patients; BSC, best supportive care; RR, response rate; PR, partial response; SD, stable disease; CBR, clinical benefit rate; wks, weeks; PFS, progression free survival; mo, month; vs, versus; mTTP, median time to progression; n/a, not applicable; OS, overall survival; yr, year published; ref, reference; A, Avapritinib; R, Regorafenib

^aNCCN compendium listed